Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

609 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Cancer vaccine].
Wada H, Doki Y, Nakayama E. Wada H, et al. Among authors: nakayama e. Nihon Rinsho. 2008 Oct;66(10):2004-7. Nihon Rinsho. 2008. PMID: 18939504 Review. Japanese.
NY-ESO-1 expression and immunogenicity in esophageal cancer.
Fujita S, Wada H, Jungbluth AA, Sato S, Nakata T, Noguchi Y, Doki Y, Yasui M, Sugita Y, Yasuda T, Yano M, Ono T, Chen YT, Higashiyama M, Gnjatic S, Old LJ, Nakayama E, Monden M. Fujita S, et al. Among authors: nakayama e. Clin Cancer Res. 2004 Oct 1;10(19):6551-8. doi: 10.1158/1078-0432.CCR-04-0819. Clin Cancer Res. 2004. PMID: 15475443
Antibody response against NY-ESO-1 in CHP-NY-ESO-1 vaccinated patients.
Kawabata R, Wada H, Isobe M, Saika T, Sato S, Uenaka A, Miyata H, Yasuda T, Doki Y, Noguchi Y, Kumon H, Tsuji K, Iwatsuki K, Shiku H, Ritter G, Murphy R, Hoffman E, Old LJ, Monden M, Nakayama E. Kawabata R, et al. Among authors: nakayama e. Int J Cancer. 2007 May 15;120(10):2178-84. doi: 10.1002/ijc.22583. Int J Cancer. 2007. PMID: 17278093 Clinical Trial.
Analysis of peripheral and local anti-tumor immune response in esophageal cancer patients after NY-ESO-1 protein vaccination.
Wada H, Sato E, Uenaka A, Isobe M, Kawabata R, Nakamura Y, Iwae S, Yonezawa K, Yamasaki M, Miyata H, Doki Y, Shiku H, Jungbluth AA, Ritter G, Murphy R, Hoffman EW, Old LJ, Monden M, Nakayama E. Wada H, et al. Among authors: nakayama e. Int J Cancer. 2008 Nov 15;123(10):2362-9. doi: 10.1002/ijc.23810. Int J Cancer. 2008. PMID: 18729190 Clinical Trial.
Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination.
Kawada J, Wada H, Isobe M, Gnjatic S, Nishikawa H, Jungbluth AA, Okazaki N, Uenaka A, Nakamura Y, Fujiwara S, Mizuno N, Saika T, Ritter E, Yamasaki M, Miyata H, Ritter G, Murphy R, Venhaus R, Pan L, Old LJ, Doki Y, Nakayama E. Kawada J, et al. Among authors: nakayama e. Int J Cancer. 2012 Feb 1;130(3):584-92. doi: 10.1002/ijc.26074. Epub 2011 May 25. Int J Cancer. 2012. PMID: 21413013
Clinical trial of the intratumoral administration of labeled DC combined with systemic chemotherapy for esophageal cancer.
Fujiwara S, Wada H, Miyata H, Kawada J, Kawabata R, Nishikawa H, Gnjatic S, Sedrak C, Sato E, Nakamura Y, Sakakibara M, Kanto T, Shimosegawa E, Hatazawa J, Takahashi T, Kurokawa Y, Yamasaki M, Nakajima K, Takiguchi S, Nakayama E, Mori M, Doki Y. Fujiwara S, et al. Among authors: nakayama e. J Immunother. 2012 Jul;35(6):513-21. doi: 10.1097/CJI.0b013e3182619cb4. J Immunother. 2012. PMID: 22735809 Clinical Trial.
[Immune monitoring and cancer vaccine].
Wada H, Doki Y, Nakayama E. Wada H, et al. Among authors: nakayama e. Nihon Rinsho. 2012 Dec;70(12):2183-8. Nihon Rinsho. 2012. PMID: 23259394 Review. Japanese.
Vaccination with NY-ESO-1 overlapping peptides mixed with Picibanil OK-432 and montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen.
Wada H, Isobe M, Kakimi K, Mizote Y, Eikawa S, Sato E, Takigawa N, Kiura K, Tsuji K, Iwatsuki K, Yamasaki M, Miyata H, Matsushita H, Udono H, Seto Y, Yamada K, Nishikawa H, Pan L, Venhaus R, Oka M, Doki Y, Nakayama E. Wada H, et al. Among authors: nakayama e. J Immunother. 2014 Feb-Mar;37(2):84-92. doi: 10.1097/CJI.0000000000000017. J Immunother. 2014. PMID: 24509171 Clinical Trial.
NY-ESO-1 Protein Cancer Vaccine With Poly-ICLC and OK-432: Rapid and Strong Induction of NY-ESO-1-specific Immune Responses by Poly-ICLC.
Takeoka T, Nagase H, Kurose K, Ohue Y, Yamasaki M, Takiguchi S, Sato E, Isobe M, Kanazawa T, Matsumoto M, Iwahori K, Kawashima A, Morimoto-Okazawa A, Nishikawa H, Oka M, Pan L, Venhaus R, Nakayama E, Mori M, Doki Y, Wada H. Takeoka T, et al. Among authors: nakayama e. J Immunother. 2017 May;40(4):140-147. doi: 10.1097/CJI.0000000000000162. J Immunother. 2017. PMID: 28338507
609 results